TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue
+70.3%
EPS
−73.7%
Free cash flow
+427.1%
Total debt
+204.2%

Quarter to June 2026, against a year earlier

60.07 2.09 +3.60%
Market cap
$8.9B
P/E
19.1×
Fwd P/E
62.4×
Dividend yield
—
F-score
5/9
Altman Z
6.29
Beneish M
0.80
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
100.28% 112.60% 102.75% 111.96%

+8 more TTM periods

Piotroski F-Score
5 4 4 4
ROA
37.70% 42.27% 54.50% 55.55%
ROIC
10.69% 11.48% 10.25% 8.91%
Return on Tangible Assets
50.33% 51.33% 93.75% 101.02%
Average Days of Receivables
183.32 204.32 181.01 182.11
Free Cash Flow per Share
0.12 (0.10) (0.17) (0.48)
Free Cash Flow
17.39 (14.19) (24.99) (70.24)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026